The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.

Lens epithelium-derived growth factor (LEDGF) is a chromatin-associated protein implicated in leukemia and HIV type 1 infection. LEDGF associates with mixed-lineage leukemia (MLL) fusion proteins and menin and is required for leukemic transformation. To better understand the molecular mechanism underlying the LEDGF integrase-binding domain (IBD) interaction with MLL fusion proteins in leukemia， we determined the solution structure of the MLL-IBD complex. We found a novel MLL motif， integrase domain binding motif 2 (IBM2)， which binds to a well-defined site on IBD. Point mutations within IBM2 abolished leukemogenic transformation by MLL-AF9， validating that this newly identified motif is essential for the oncogenic activity of MLL fusion proteins. Interestingly， the IBM2 binding site on IBD overlaps with the binding site for the HIV integrase (IN)， and IN was capable of efficiently sequestering IBD from the menin-MLL complex. A short IBM2 peptide binds to IBD directly and inhibits both the IBD-MLL/menin and IBD-IN interactions. Our findings show that the same site on IBD is involved in binding to MLL and HIV-IN， revealing an attractive approach to simultaneously target LEDGF in leukemia and HIV.